Mesoblast Limited (ASX:MSB)
3.070
+0.120 (4.07%)
At close: Jan 9, 2026
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M USD with 191.39% growth. Mesoblast had revenue of $7.02M in the half year ending June 30, 2025, with 458.55% growth.
Revenue
$17.20M
Revenue Growth
+191.39%
P/S Ratio
150.14
Revenue / Employee
$212.32K
Employees
81
Market Cap
3.94B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | 16.72M | -619.00K | -3.57% |
| Jun 30, 2018 | 17.34M | 14.93M | 618.95% |
| Jun 30, 2017 | 2.41M | -40.14M | -94.33% |
| Jun 30, 2016 | 42.55M | 22.79M | 115.31% |
| Jun 30, 2015 | 19.76M | - | - |
| Jun 30, 2014 | - | - | - |
| Jun 30, 2013 | - | - | - |
| Jun 30, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Mesoblast News
- 1 day ago - Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales - Benzinga
- 1 day ago - Mesoblast Surges As Flagship Product Ryoncil Delivers Strong Quarterly Sales Growth - Nasdaq
- 1 day ago - Ryoncil® Sales Increase 60% in December Quarter to US$35.1M - GlobeNewsWire
- 2 days ago - ASX 200 LIVE: ASX trims gains; Woodside, Santos rally on oil spike, Rio down 5pc - The Australian Financial Review
- 8 days ago - Mesoblast (MESO) Appoints New Non-Executive Chair - GuruFocus
- 8 days ago - Mesoblast Chair Jane Bell To Retire; Appoints Philip Facchina As Non-executive Chair - Nasdaq
- 8 days ago - Mesoblast Announces Changes to Board of Directors' Leadership Roles - GlobeNewsWire
- 11 days ago - Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line - GlobeNewsWire